Clene Inc (CLNN)

Clene's stock experienced an oversubscribed registered direct offering in January 2026, raising $28 million to fund operations into Q3 2026. The FDA granted an in-person Type C meeting to discuss biomarker data supporting CNM-Au8, showing a 78% reduced mortality risk in certain ALS patients. Despite these positive developments, the stock has shown volatility, with a significant drop on January 13, 2026, and insider selling activity. Clene missed analysts' consensus estimates for revenue in its last quarterly earnings report, and the stock price has drifted lower since then.

Clene Inc. has shown a historical seasonal pattern with a "Buy Date of January 6 and a Sell Date of March 31", resulting in a geometric average return of 20.25% above the S&P 500 Total Return Index over the past six years. The demand for Clene's products and services is primarily driven by clinical trial outcomes, regulatory approvals, and the prevalence of neurodegenerative diseases, rather than traditional consumer seasonality.

Clene, Inc. is a clinical-stage biopharmaceutical company focused on developing clean-surfaced nanotechnology therapeutics to improve mitochondrial health and neuronal function for neurodegenerative diseases like ALS, Parkinson's, and MS. Their primary product, CNM-Au8, is undergoing clinical trials, while they also develop treatments for infectious diseases and market dietary supplements.

Clene, Inc. is headquartered in Salt Lake City, Utah, with R&D and manufacturing in Maryland. They collaborate with institutions and clinical sites in North America and Australia for research and clinical trials.

Clene's brand reputation has been influenced by clinical progress and regulatory interactions, with positive analyst ratings and promising biomarker data for CNM-Au8. Financial challenges, insider selling, and stock volatility pose risks to its reputation. Ongoing discussions with the FDA and preparation for an NDA submission for CNM-Au8 in ALS are critical turning points.

Clene Inc.'s ownership is a mix of institutional investors (7.02%), insiders (72.21%), and public companies and individual investors (20.77%). Major institutional owners include Scoggin Management Lp and Vanguard Group Inc. Chidozie Ugwumba and Jonathon Gay are major individual shareholders.